Drug intelligence / Profile preview

niridazole

Development stage
Preclinical
Lead developer
Novartis
Modality
Small Molecules
Administration
Oral
01

Overview

Niridazole is a small molecule antiparasitic drug classified as a nitrothiazole. It is primarily used as a schistosomicide for the treatment of schistosomiasis, an infection caused by flatworms of the genus Schistosoma. Niridazole acts by rapidly concentrating in the parasite, where it inhibits oogenesis and spermatogenesis, disrupts glycogen metabolism through inhibition of phosphofructokinase, and may also inhibit DNA synthesis in schistosomes. The drug can cause significant central nervous system toxicity (including hallucinations and convulsions) and allergic reactions in sensitive individuals. Although highly effective against schistosomes, its use has declined due to safety concerns. Niridazole has also been investigated for other parasitic diseases such as dracunculiasis (guinea worm disease), tungiasis, and periodontitis[1][4][5].

Brand names
AmbilharAmbilar
Other names
nitrothiazolenitrothiamidazolniridazolum
02

Targets

PFK (Phosphofructokinase-1 liver type)

Beyond the preview

Go deeper on niridazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on niridazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call